Q3 2024 Bavarian Nordic A/S Earnings Call- Q&A session Transcript
Key Points
- Bavarian Nordic AS (BVNKF) reported strong growth in its travel health portfolio, surpassing revenue consensus for travel health and public preparedness.
- The company is preparing for the launch of its new Chikungunya vaccine, with regulatory reviews underway in the US and Europe, and a planned approval for next year.
- Bavarian Nordic AS (BVNKF) has secured strong orders for its pox vaccine for the next year, with 2.4 billion DKK in revenues already confirmed for its public preparedness business.
- The company successfully completed the tech transfer for its rabies vaccine from GSK, achieving regulatory approvals on time and on budget, which is expected to improve gross margins.
- Bavarian Nordic AS (BVNKF) has expanded its commercial presence in new markets such as the UK, Canada, and France to support the upcoming Chikungunya vaccine launch.
- The market for Bavarian Nordic AS (BVNKF)'s cholera and typhoid vaccines has not recovered since COVID-19, leading to negative growth and product returns.
- The company faces logistical challenges in delivering vaccines to African nations, which could impact revenue recognition for the current year.
- There is uncertainty regarding future demand for vaccine manufacturing in Africa, which affects decisions on tech transfer investments.
- Bavarian Nordic AS (BVNKF) has a wide revenue guidance range due to uncertainties in logistics and supply chain execution.
- The company is facing challenges in expanding its vaccine label to include pediatric use, requiring careful consideration of ethical and risk factors.
¸ - /-
Welcome everyone to this Q3 update from Bavarian Nordic. Yes, my name is Rolf Sass Sørensen in the Investor Relations on quite a dramatic day for the company. Today here, as usual, we have our President and CEO for Paul Chaplin and our CFO Henrik Juuel you to provide comments and the presentation on our Q3 and nine month period presentation. And after that, it will be followed by Q&A as usual.
Before we start, I just want to quickly to go through the forward-looking statements, forward-looking statements involve risks, uncertainties and other factors. Many of which are outside our control that could cause actual results to differ materially from the results discussed, forward-looking statements include statements concerning our plans, objectives, goals, future events, performance, and other information that is not historical information.
We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
